The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of a metastatic site on circulating tumor DNA (ctDNA) analysis in patients (pts) with metastatic colorectal cancer (mCRC).
 
Hideaki Bando
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yoshiaki Nakamura
Research Funding - Chugai Pharma (Inst); Genomedia (Inst); Guardant Health (Inst); Taiho Pharmaceutical (Inst)
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Ono Yakuhin; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sysmex (Inst); Takeda (Inst)
 
Manabu Shiozawa
No Relationships to Disclose
 
Hisateru Yasui
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; TERUMO; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Taito Esaki
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
Research Funding - Amgen Astellas BioPharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQVIA (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Ohta
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Novartis; Teijin Pharma
 
Tadamichi Denda
Honoraria - Sawai Pharmaceutical Co
Speakers' Bureau - Sysmex
Research Funding - MSD (Inst); Ono Pharmaceutical (Inst)
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD K.K; Nippon Kayaku; Sanofi; Sysmex; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bristol-Myers Squibb Japan; MSD K.K; Takeda
Research Funding - Chugai Pharma; Lilly Japan; Nihonkayaku; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma
 
Masahiro Goto
Honoraria - DAIICHI SANKYO COMPANY,LIMITED; Eisai; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma; Lilly Japan; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Medical & Biological Laboratories; Merck; MSD K.K; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Eiji Shinozaki
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Nobuhisa Matsuhashi
No Relationships to Disclose
 
Masayuki Hata
No Relationships to Disclose
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck; Takeda
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)